Genentech Inc., has voluntarily withdrawn Raptiva from the market. Raptiva is a psoriasis drug that has been linked to progressive multifocal leukoencephalopathy (PML), a rare brain infection. PML is often fatal. Recently, Genentech disclosed that three patients taking Raptiva had developed PML since October 2008, with two of those patients dying. In March 2009, Genentech updated the Raptiva label to reflect the heightened risk of PML. Genentech later decided that Raptiva’s risks outweighed its benefits, particularly since there is no way to mitigate the risks.
Raptiva was approved by the FDA in 2003 for the treatment of psoriasis. It works by suppressing the T-cells in the immune system. According to Genentech, since Raptiva’s approval, approximately 48,000 people worldwide have taken Raptiva, and 2,000 U.S. patients currently use it. Genentech advises doctors to work with patients to find alternative treatmens for their psoriasis. Patients should not abruptly stop taking Raptiva, as that could make their psoriasis worse. No new prescriptions should be written for Raptiva, but it will be available to current patients until June 8.
If you or someone you know has been injured by taking Raptiva, contact Sheller, P.C.. Sheller aggressively and passionately represents individuals and classes of individuals who have suffered injuries. Contact us to discuss whether you have a potential claim regarding Raptiva. Sheller lawyers have successfully represented people who have been injured by various prescription and over-the-counter drugs. We are dedicated to helping our clients obtain the remedies that they deserve.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.